Skip to main content

Table 5 Summary of MRSS values by treatment

From: Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study

Treatment group

n

MRSS, mean (SD)

Day 1

Day 85

Change from day 1 to day 85

Placebo

4

22.8 (7.5)

25.0 (7.2)

2.3 (6.1)

MEDI-551 0.1 mg/kg

1

31.0 (NA)

17.0 (NA)

-14.0 (NA)

MEDI-551 0.3 mg/

4

23.5 (7.6)

17.3 (5.1)

-6.3 (3.5)

MEDI-551 1.0 mg/kg

6

20.0 (9.8)

15.5 (8.7)

-4.5 (1.5)

MEDI-551 3.0 mg/kg

6a

23.3 (12.8)

17.8 (13.1)

-6.6 (3.0)

MEDI-551 10.0 mg/kg

7

24.0 (5.1)

20.4 (7.7)

-3.6 (5.7)

Combined MEDI-551

24b

23.0 (8.7)

17.9 (8.5)

-5.4 (4.2)

  1. MRSS modified Rodnan skin score
  2. aAt day 85, n = 5
  3. bAt day 85, n = 23